The US Food and Drug Administration (FDA) has accepted MSD’s doravirine/islatravir (DOR/ISL) new drug application (NDA) for ...

Rahway, New Jersey Wednesday, July 16, 2025, 17:30 Hrs [IST] ...

TPN-101, a potent nucleoside reverse transcriptase inhibitor that specifically inhibits the LINE-1 reverse transcriptase.

Use of nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs) is associated with an increased risk for primary ...

Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, ...

The inhibition of HIV-1’s replicative machinery remains a cornerstone in the battle against AIDS. Central to this approach are inhibitors targeting reverse transcriptase (RT) and integrase.

Announced at the International AIDS Society (IAS) 2025 conference taking place from 13-17 July in Kigali, Rwanda, MSD has launched two Phase III trials, EXPrESSIVE-10 and EXPrESSIVE-11, which will ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluating the safety and efficacy of MK-8527, an ...